Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion.
Silvia M Mihaila, João Faria, Maurice F J Stefens...
https://pubmed.ncbi.nlm.nih.gov/32545617Actively Recruiting
Age: 18Years +
All Genders
ID06750575
Effect of Furosemide on Protein-Bound Uremic Toxins in Blood and Urine of Patients with Chronic Kidney Disease
Led by UMC Utrecht · Updated on 2024-12-27
34
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
Sponsors
U
UMC Utrecht
Lead Sponsor
M
Maastricht University, MERLN Institute for Technology-Inspired Regenerative Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to explore how the diuretic furosemide affects certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). These toxins tend to build up in CKD and are linked to worse health outcomes. The study focuses on understanding the impact of furosemide on PBUT levels in the blood and their removal through urine in patients with CKD stage 3-5 who require furosemide treatment as part of their routine care. Participants will receive furosemide as prescribed by their nephrologist without changes due to the study. Before starting furosemide, blood pressure will be measured, and blood and urine samples will be collected, including a 12-hour urine collection. Between one and four weeks after beginning furosemide, blood pressure and multiple blood and urine samples will be collected at specific times related to medication intake to monitor toxin levels and excretion. This includes blood samples before and about 90 minutes after taking furosemide, and urine samples collected 60-120 minutes after intake. During the study, participants will make two visits to the study center, which will be coordinated with their routine check-ups when possible. Researchers will measure plasma levels of several PBUTs three times during the study period. They will also track urine collections and blood pressure. The main goal is to compare PBUT plasma levels before and after furosemide treatment. Data will be analyzed statistically to understand the relationship between furosemide use and toxin levels, with minimal risk to participants.
CONDITIONS
Official Title
Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of chronic kidney disease stage 3-5 with eGFR below 60 mL/min/1.73m2 for at least three months
- Indication to start furosemide treatment as part of routine care
- Willingness to participate and signed informed consent
You will not qualify if you...
- Current use of furosemide treatment
- Liver disease with hyperbilirubinemia
- Receiving any type of renal replacement therapy (peritoneal dialysis, haemodialysis)
- End-stage renal failure without residual urine production
- Starting medications simultaneously with furosemide that may affect PBUT excretion or binding
- Incapacity to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Trial Site Locations
Total: 1 location
1
University Medical Center Utrecht (UMCU)
Utrecht, Utrecht, Netherlands, 3584 CX
Actively Recruiting
Loading map...
Research Team
D
Dian P Bolhuis, MD, MSc
K
Karin GF Gerritsen, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here